focus -WSS

focus

author：focus 2025-10-01 22:58:08 - browse：5184

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Pope Francis asks Church to identify 21st

focus

WSS

Long Covid research funding gets a major boost from NIH

City of Memphis, police chief oppose effort to delay lawsuit in Tyre Nichols case

Congress must protect the remaining independent doctors

Too many hospitalized Covid

Bernie Sanders gets little from pharma CEOs on drug prices

Resistance to opioid

knowledge

focus

entertainment

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Trump demands the U.S. pay no more for drugs than other countries … again

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Alkermes shareholders re

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Psychedelics group wrestles with new pharma identity

Artificial intelligence use in health care faces greater scrutiny in 2024

Moonlake's readout produced a cash windfall. Risks remain

ACIP vaccine advisory panel sees its vacancies filled

hotspot

Juul documents reveal insider tactics on political lobbying

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

EU moves toward latest gene techniques in food production to counter climate change, shortages

City of Memphis, police chief oppose effort to delay lawsuit in Tyre Nichols case

Long Covid research funding gets a major boost from NIH

3 protesters arrested at Wimbledon after interrupting matches by throwing confetti on court

Wikipedia

focus

explore

knowledge